Oral Solid Dosage Pharmaceutical Formulation Market to Reach USD 1,349.27 Billion by 2032

Got story updates? Submit your updates here. ›

The global Oral Solid Dosage (OSD) Pharmaceutical Formulation Market is set to surge from USD 779.44 Billion in 2024 to USD 1,349.27 Billion by 2032, at a 7.1% CAGR. This growth is attributed to the rise of oral GLP-1 therapies and a significant manufacturing reshoring trend in North America. The industry is transitioning toward continuous manufacturing and enhanced bioavailability, solidifying OSD's role as the primary vehicle for global drug delivery.

Why it matters

The trajectory toward USD 1,349.27 billion is fueled by a structural shift in how medicines are engineered. The industry is rapidly transitioning from traditional batch processing to Continuous Manufacturing (CM) as a primary driver of efficiency, reducing facility footprints and shortening technology transfer timelines. This evolution allows manufacturers to respond instantly to market volatility and drug shortages.

The details

The evolution of oral delivery is defined by the "injectable-to-oral" transition of high-value metabolic therapies. Manufacturers are racing to stabilize large-molecule peptides for gastric absorption, particularly in the obesity and diabetes sectors. Simultaneously, 3D printing is moving from laboratory prototypes to clinical reality, allowing for precise dose titration and polypill combinations for geriatric populations.

• The global OSD landscape is being redrawn by a "Local-for-Local" manufacturing mandate, with North America remaining the dominant revenue engine.
• Since early 2025, over $13 billion has been committed to domestic OSD facilities in North America to mitigate the risks of international drug shortages and trade volatility.
• Europe is pivoting toward a "Green OSD" framework, integrating eco-design into tablet production to reduce solvent use and carbon-neutral blister packaging.
• Asia-Pacific stands as the fastest-growing region, fueled by "Pharma 4.0" initiatives in India and China, which are evolving into global innovation centers.
• In late 2025, Gilead Sciences broke ground on a new 180,000-square-foot Technical Development Center in California, integrating autonomous robotics and real-time digital monitoring to accelerate the production of next-generation therapies.